- Home
- YCBD vs ZVSA Comparison
YCBD vs ZVSA Comparison
Compare YCBD & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- ZVSA
- Stock Information
- Founded
- YCBD 2015
- ZVSA 2014
- Country
- YCBD United States
- ZVSA United States
- Employees
- YCBD N/A
- ZVSA N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- ZVSA Health Care
- Exchange
- YCBD Nasdaq
- ZVSA Nasdaq
- Market Cap
- YCBD 1.6M
- ZVSA 1.5M
- IPO Year
- YCBD N/A
- ZVSA N/A
- Fundamental
- Price
- YCBD $0.50
- ZVSA $1.42
- Analyst Decision
- YCBD
- ZVSA Strong Buy
- Analyst Count
- YCBD 0
- ZVSA 1
- Target Price
- YCBD N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- YCBD 3.2M
- ZVSA 2.2M
- Earning Date
- YCBD 02-11-2025
- ZVSA 11-14-2024
- Dividend Yield
- YCBD N/A
- ZVSA N/A
- EPS Growth
- YCBD N/A
- ZVSA N/A
- EPS
- YCBD N/A
- ZVSA N/A
- Revenue
- YCBD $19,482,167.00
- ZVSA N/A
- Revenue This Year
- YCBD $13.00
- ZVSA N/A
- Revenue Next Year
- YCBD N/A
- ZVSA N/A
- P/E Ratio
- YCBD N/A
- ZVSA N/A
- Revenue Growth
- YCBD N/A
- ZVSA N/A
- 52 Week Low
- YCBD $0.31
- ZVSA $0.98
- 52 Week High
- YCBD $1.34
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- YCBD 53.41
- ZVSA 57.25
- Support Level
- YCBD $0.42
- ZVSA $1.31
- Resistance Level
- YCBD $0.82
- ZVSA $1.95
- Average True Range (ATR)
- YCBD 0.12
- ZVSA 0.19
- MACD
- YCBD 0.01
- ZVSA 0.04
- Stochastic Oscillator
- YCBD 34.18
- ZVSA 44.21
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD and hempMD. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.